MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Price, Forecast & Analysis
USA - NASDAQ:MREO - US5894921072 - ADR
MREO Key Statistics, Chart & Performance
The current stock price of MREO is 1.82 USD. In the past month the price decreased by -14.55%. In the past year, price decreased by -51.08%.
MREO Latest News, Press Relases and Analysis
MREO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.75 | 413.15B | ||
| AMGN | AMGEN INC | 15.73 | 185.19B | ||
| GILD | GILEAD SCIENCES INC | 15.53 | 157.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.09 | 111.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 76.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 906.47 | 60.60B | ||
| INSM | INSMED INC | N/A | 42.62B | ||
| NTRA | NATERA INC | N/A | 29.32B | ||
| BIIB | BIOGEN INC | 10.09 | 24.75B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.06 | 21.56B | ||
| INCY | INCYTE CORP | 16.18 | 20.29B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.17 | 13.75B |
Related stock screener links
About MREO
Company Profile
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Company Info
MEREO BIOPHARMA GROUP PL-ADR
One Cavendish Place, Fourth Floor
London W1G0QF GB
CEO: Denise Scots-Knight
Employees: 36
Phone: 443330237300
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What does MEREO BIOPHARMA GROUP PL-ADR do?
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
What is the current price of MREO stock?
The current stock price of MREO is 1.82 USD. The price increased by 2.82% in the last trading session.
What is the dividend status of MEREO BIOPHARMA GROUP PL-ADR?
MREO does not pay a dividend.
What is the ChartMill technical and fundamental rating of MREO stock?
MREO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for MREO stock?
MEREO BIOPHARMA GROUP PL-ADR (MREO) currently has 36 employees.
What is the next earnings date for MREO stock?
MEREO BIOPHARMA GROUP PL-ADR (MREO) will report earnings on 2026-03-23, after the market close.
What is the ownership structure of MEREO BIOPHARMA GROUP PL-ADR (MREO)?
You can find the ownership structure of MEREO BIOPHARMA GROUP PL-ADR (MREO) on the Ownership tab.
MREO Technical Analysis
MREO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MREO. No worries on liquidiy or solvency for MREO as it has an excellent financial health rating, but there are worries on the profitability.
MREO Financial Highlights
Over the last trailing twelve months MREO reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS decreased by -50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.29% | ||
| ROE | -91.67% | ||
| Debt/Equity | 0 |
MREO Forecast & Estimates
15 analysts have analysed MREO and the average price target is 7.14 USD. This implies a price increase of 292.31% is expected in the next year compared to the current price of 1.82.